Olema Pharmaceuticals (OLMA) Share-based Compensation (2020 - 2026)
Olema Pharmaceuticals (OLMA) posted quarterly Share-based Compensation of $10.1 million for Q1 2026, up 131.8% year-over-year from $4.4 million in Q1 2025, and up 181.68% quarter-over-quarter from -$12.4 million in Q4 2025.
Olema Pharmaceuticals (OLMA) Share-based Compensation (2020 - 2026) Analysis & Trends
Olema Pharmaceuticals (OLMA) has reported Share-based Compensation for 7 consecutive years, with $10.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Share-based Compensation rose 131.8% year-over-year to $10.1 million; the TTM figure through Mar 2026 stood at $2.9 million (down 70.46% YoY), while the FY2025 annual figure was $32.1 million, changed N/A from the prior year.
- Share-based Compensation rose to $10.1 million in Q1 2026 per OLMA's latest filing, from -$12.4 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $16.9 million in Q4 2023 and bottomed at -$12.4 million in Q4 2025.
- Historically, Share-based Compensation has averaged $3.1 million across 5 years, with a median of $4.2 million in 2025.
- Annual changes were most pronounced in 2023 — Share-based Compensation soared 15011.61% — and 2025, when it sank 2717.23%.
- Olema Pharmaceuticals' Share-based Compensation stood at $112000.0 in 2022, then jumped by 15011.61% to $16.9 million in 2023, then sank by 102.61% to -$441000.0 in 2024, then tumbled by 2717.23% to -$12.4 million in 2025, then soared by 181.68% to $10.1 million in 2026.
- Business Quant data shows OLMA's Share-based Compensation at $10.1 million in Q1 2026, -$12.4 million in Q4 2025, and $4.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Olema Pharmaceuticals | 930.10 Mn | 930.10 Mn | - | 12.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 12.90 Mn |
| Jun 30, 2026 | 12.90 Mn |
| Mar 31, 2026 | 10.15 Mn |
| Mar 31, 2026 | 10.15 Mn |
| Dec 31, 2025 | -12.42 Mn |
| Dec 31, 2025 | -12.42 Mn |
| Sep 30, 2025 | 4.25 Mn |
| Sep 30, 2025 | 4.25 Mn |
| Jun 30, 2025 | 896,000.00 |
| Jun 30, 2025 | 896,000.00 |
| Mar 31, 2025 | 4.38 Mn |
| Mar 31, 2025 | 4.38 Mn |
| Dec 31, 2024 | -441,000.00 |
| Dec 31, 2024 | -441,000.00 |
| Sep 30, 2024 | 54,000.00 |
| Sep 30, 2024 | 54,000.00 |
| Jun 30, 2024 | 5.72 Mn |
| Jun 30, 2024 | 5.72 Mn |
| Mar 31, 2024 | 205,000.00 |
| Mar 31, 2024 | 205,000.00 |